How does the EBMT support the development of CAR T therapies?

During the 2nd European CAR T Cell Meeting in Sitges, ES, the Multiple Myeloma Hub was delighted to speak to Nicolaus Kröger, University Hospital Hamburg, Hamburg, DE. We asked: How does the EBMT support the development of CAR T therapies?

Nicolaus Kröger explains that the EBMT is highly committed to the development of CAR T cells. He tells us that EBMT has received a positive opinion by the European Medicines Agency thus the EBMT is open to register all CAR T cells around Europe. He also discusses the new registry that was established by the EBMT with CIBMTR to collect CAR T data. Lastly, he talks about the development of the CAR T cell governance structure, where all stakeholders form a group with the shared aim to develop CAR T cells in Europe.